echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dust settled! New base to BMS, new biological giant will be born?

    Dust settled! New base to BMS, new biological giant will be born?

    • Last Update: 2019-11-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In less than a year, BMS finally completed a $74 billion acquisition of celgene When the "dust settled" announcement was released (November 21), BMS's share price rose slightly to $57.09, higher than when the acquisition was announced in January this year Xinji's official website has updated "belongs to Bristol Myers Squibb" to remind that after the acquisition, Xinji now belongs to the wholly-owned subsidiary of BMS, which has 9 products and annual sales of more than 1 billion US dollars Giovanni caforio, chairman and CEO of BMS, said: "it's an exciting day for the two companies because of the combination of science, innovative drugs and excellent talents With our leading product franchises in oncology, hematology, immunology and cardiovascular disease, and one of the industry's most diverse and promising product lines, we will realize our vision of changing patients' lives through science " It is not easy for "BMS + new base" to become the first "BMS acquires new base" in the tumor market After BMS announced this amazing plan and huge amount of acquisition at the beginning of the year, the leaders of the two companies have been dealing with the opposition to the merger, with some major stakeholders, shareholders and consortiums holding opposition to the deal BMS's board of Directors believes that the combined company will have the conditions to support long-term growth To defend the deal, caforio said: "the merger will create the world's' first 'oncology product line in the field of solid tumors and blood tumors." The combined R & D pipeline pillar will be based on the "blockbuster" checkpoint inhibitors opdivo, yevoy and the best-selling myeloma drugs Revlimid and pomalyst According to Bristol Myers Squibb's 2018 financial report, the total revenue is US $22.561 billion, with opdivo supporting nearly one-third of the revenue, reaching US $6.735 billion, with sales growth of 36%, maintaining growth for five consecutive years; yevoy's revenue is US $1.33 billion, which is more expected to be based on the product mix with opdivo In 2018, Xinji's total revenue reached US $15.281 billion, with Revlimid and pomalyst occupying most of the country's market share continuing to grow due to the expansion of indications, with Revlimid's sales reaching US $10 billion and pomalyst's sales reaching US $2.04 billion BMS believes that the field of multiple myeloma (MS) treatment will continue to grow in the future "The MS market is evolving into a market with new targets and new models, such as the addition of BCMA, celmod and car-t therapies," carafio said After the acquisition, BMS may launch four products in the hematology market in the next one to two years, and two products, Tyk2 and ozanimod, in the field of immunotherapy and inflammatory therapy It is estimated that the potential revenue of six products will exceed US $15 billion After the announcement of the acquisition, BMS also helped Xinji maintain the patent cliff of Revlimid and promote the approval progress of several drug regulators In August, the US FDA approved the new ingrebic (fedratinib) for the treatment of middle-risk-2 and high-risk primary or secondary myelofibrosis in adult patients In November, reblozyl (luspatercept AAMT) was approved for the treatment of anemia in adult patients with β - thalassemia who need regular infusion of red blood cells This is the first drug approved by FDA for the treatment of β - thalassemia related anemia, and the first and only red blood cell ripening agent In order to succeed in the acquisition, Xinji sold anti-inflammatory best-selling drugs, which was expected to be completed in the third quarter of 2019, but lasted until the end of the year In addition to investors' objections, otezla (apremillast), a "blockbuster" drug for psoriasis and psoriatic arthritis, has also become a barrier to acquisitions Previously, the Federal Trade Commission (FTC) had insisted on stripping otezla, the new base's best-selling drug, before the two companies could continue to merge FTC believes that otezla's indications have a high overlap with orencia, a listed psoriatic arthritis drug of BMS, and bms-986165, an oral Tyk2 inhibitor under research, which will make the combined company have a large stake in the psoriasis market, causing anti competitive concerns In August, Xinji identified a buyer for its Otezla Amgen agreed to buy the psoriasis drug for $13.4 billion In 2018, the drug's sales revenue reached US $1.6 billion, an increase of 26% compared with that in 2017 At present, three indications of plaque psoriasis, psoriatic arthritis and adult Behcet's disease have been approved in the United States With the completion of the merger with Xinji, Amgen also announced yesterday that "the acquisition of otezla has also been completed." "The transaction funds will be used to repay the debt," BMS said Reference [1] bmscompletes $74 billion celgenetakeover [2] bmsceogiovannica foriolayesoutreasoning for $74 billion acquisition of celgene.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.